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ABSTRACT
Purpose: Liver metastasis develops in >50% of patients with colorectal cancer (CRC), and is a leading
cause of CRC-related mortality. We aimed to identify which inhibitory immune checkpoint pathways can
be targeted to enhance functionality of intra-tumoral T-cells in mismatch repair-proﬁcient liver metastases
of colorectal cancer (LM-CRC).
Methodology: Intra-tumoral expression of multiple inhibitory molecules was compared among mismatch
repair-proﬁcient LM-CRC, peritoneal metastases of colorectal cancer (PM-CRC) and primary CRC.
Expression of inhibitory molecules was also analyzed on leukocytes isolated from paired resected
metastatic liver tumors, tumor-free liver tissues, and blood of patients with mismatch repair-proﬁcient LM-
CRC. The effects of blocking inhibitory pathways on tumor-inﬁltrating T-cell responses were studied in ex
vivo functional assays.
Results: Mismatch repair-proﬁcient LM-CRC showed higher expression of inhibitory receptors on intra-
tumoral T-cells and contained higher proportions of CD8C T-cells, dendritic cells and monocytes than
mismatch repair-proﬁcient primary CRC and/or PM-CRC. Inhibitory receptors LAG3, PD-1, TIM3 and CTLA4
were higher expressed on CD8C T-cells, CD4C T-helper and/or regulatory T-cells in LM-CRC tumors
compared with tumor-free liver and blood. Antibody blockade of LAG3 or PD-L1 increased proliferation
and effector cytokine production of intra-tumoral T-cells isolated from LM-CRC in response to both
polyclonal and autologous tumor-speciﬁc stimulations. Higher LAG3 expression on intra-tumoral CD8C T-
cells associated with longer progression-free survival of LM-CRC patients.
Conclusion: Mismatch repair-proﬁcient LM-CRC may be more sensitive to immune checkpoint inhibitors
than mismatch repair-proﬁcient primary CRC. Blocking LAG3 enhances tumor-inﬁltrating T-cell responses
of mismatch repair-proﬁcient LM-CRC, and therefore may be a new promising immunotherapeutic target
for LM-CRC.
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Introduction
Colorectal cancer (CRC) is the third most common cause of
cancer-related mortality worldwide.1-3 More than 50% of CRC
patients develop metastatic disease to their liver over the course
of their life,4 and liver metastasis is a leading cause of death
from CRC.5-7 Unfortunately, surgical resection of isolated liver
metastases of CRC (LM-CRC) is curative in only 20%-30% of
patients,8,9 and systemic therapy provides limited survival ben-
eﬁt.10 Patients with unresectable LM-CRC have a poor progno-
sis with a median survival of only two years.11 Therefore, there
is a pressing need for more effective therapeutic strategies for
LM-CRC.
The immune system plays a crucial role in cancer surveil-
lance and elimination, and antibody blockade of inhibitory
immune checkpoint pathways that suppress anti-tumor T-cell
immunity and assist tumor immune evasion,12-16 has recently
emerged as an attractive treatment option for multiple types
of malignancies.17-21 Targeting the PD-1/PD-L1 inhibitory
pathway has resulted in objective responses in 17%-28% of
advanced melanoma patients, 12%-27% of renal cell cancer
patients, 10%-18% of non-small cell lung cancer patients and
20% of advanced hepatocellular carcinoma patients.22-25 In
contrast, CRC patients hardly respond to PD-1 and PD-L1
blocking antibodies,23-26 except for the minority of patients
who are with mismatch repair (MMR)-deﬁcient CRC.27,28 A
defective MMR enzyme system occurs in 10%-20% of CRC
tumors and results in microsatellite instability, which is used
as a molecular marker of MMR-deﬁciency.29 It has been
hypothesized that the observed difference in responsiveness
to PD-1/PD-L1 blockade between MMR-deﬁcient and MMR-
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proﬁcient CRC is related to the higher numbers of somatic
mutations in MMR-deﬁcient tumors, due to the reduced abil-
ity to repair DNA damage. The increased mutation rate may
result in the presence of more mutation-encoded neo-anti-
gens in the tumors, which elicit stronger anti-tumor T cell
responses.27 Indeed, MMR-deﬁcient CRC tumors are charac-
terized by denser CD8C T cell inﬁltration.30 They also have
higher expression levels of inhibitory checkpoint molecules,
probably to resist immune-mediated tumor elimination.31
Together, enhanced immune cell inﬁltration and upregulation
of inhibitory immune checkpoints may render MMR-deﬁ-
cient CRC more sensitive to PD-1/PD-L1 blockade than
MMR-proﬁcient CRC.
In LM-CRC the incidence of MMR deﬁciency is low,32 and
it may therefore be expected that LM-CRC poorly respond to
immune checkpoint inhibitors. Nevertheless, these tumors
contain immune inﬁltrates, and increased numbers of tumor-
inﬁltrating CD8C T cells are positively associated with overall
survival and response to chemotherapy,33,34 indicating that
intra-tumoral T cell immunity is an important determinant of
LM-CRC progression. In addition, MMR-proﬁcient LM-CRC
are immunologically distinct from primary CRC in terms of
immune inﬁltration.35 Moreover, the unique immune environ-
ment in the liver36 favors immunological tolerance,36 and one
of the mechanisms used by the liver to resist immune
responses is the induction of expression of inhibitory receptors
on hepatic T cells37,38 and their ligands on hepatocytes and
other liver tissue cells.39 Previously we have observed that
intra-tumoral CD8C cytotoxic T cells (CTL) and CD4C T
helper cells (Th) are functionally compromised in LM-CRC,40
and we also demonstrated that the suppression mediated by
intra-tumoral regulatory T cells (Treg) in LM-CRC can be
alleviated by blocking the inhibitory receptor CTLA4 and acti-
vating the stimulatory receptor GITR.41 However, the expres-
sion and functional roles of inhibitory receptor-ligand
pathways in regulating tumor-inﬁltrating effector T cell
responses have not been studied yet in LM-CRC.
Therefore, the aim of this study was to determine
whether inhibitory immune checkpoint pathways can be
targeted to enhance the functionality of tumor-inﬁltrating
lymphocytes (TIL) in MMR-proﬁcient LM-CRC. We mea-
sured the expression of inhibitory receptors and their
ligands on leukocytes isolated from paired resected meta-
static liver tumors, tumor-free liver tissues (TFL) and blood
of patients with LM-CRC, and compared their expression
levels with those on leukocytes isolated from peritoneal
metastasis of CRC (PM-CRC) and primary CRC. In
addition, we studied the effects of antibody blockade of
inhibitory pathways on TIL responses of LM-CRC in ex
vivo functional assays.
Results
Comparison of immune inﬁltrates and expression
of inhibitory molecules among MMR-proﬁcient liver
metastases, peritoneal metastases and primary CRC
To speculate whether TIL in CRC tumors at different anatomi-
cal sites may differ in sensitivity to checkpoint inhibitors, we
ﬁrst compared frequencies of T cell and antigen-presenting cell
(APC) subsets, as well as their expression of inhibitory mole-
cules, between MMR-proﬁcient LM-CRC, primary CRC, and
metastases outside the liver. Two in all LM-CRC tumors and
three out of twelve primary CRC tumors that we collected were
MMR-deﬁcient, whereas all eleven PM-CRC tumors
were MMR-proﬁcient (Table 1 and Supplementary Table S1).
The data of the ﬁve patients with MMR-deﬁcient tumors are
shown in Supplementary Fig. S1.
We observed several interesting differences among
MMR-proﬁcient tumors from different anatomical locations.
Firstly, both LM-CRC and PM-CRC contained signiﬁcantly
higher frequencies of CD8C CTL and signiﬁcantly lower fre-
quencies of CD4CFoxp3¡ Th than primary CRC, while fre-
quencies of Treg were similar in CRC tumors at all three
sites (Fig. 1A). Secondly, CD8C CTL in LM-CRC displayed
a higher frequency of PD1C cells than those in primary
CRC, and also contained higher frequencies of TIM3C and
LAG3C cells than those in PM-CRC, while CD4C Th in
LM-CRC displayed a higher frequency of LAG3C cells than
those in PM-CRC (Fig. 1B). Thirdly, CD4CFoxp3C Treg in
LM-CRC contained higher frequencies of PD-1C and
TIM3C cells than those in primary CRC and PM-CRC, and
also displayed a higher frequency of LAG3C cells than those
in PM-CRC (Fig. 1B). Finally, LM-CRC contained signiﬁ-
cantly higher frequencies of myeloid dendritic cells (mDC)
and monocytes than primary CRC (Fig. 1C), which not
only can present tumor antigens to T cells but also express
the inhibitory ligands PD-L1 (for PD-1), galectin 9 (for
TIM3), MHC class II molecules (for LAG3), CD86 and
CD80 (for CTLA4) (Fig. 1D). Hierarchical clustering analy-
sis showed that the immunological data of most LM-CRC
patients clustered together as did the data of most primary
CRC patients (Supplementary Fig. S2). Together, these data
indicate that the CD8C CTL:Treg ratio, which is critical for
Table 1. Patient characteristics.
LM-CRC (n D 53) PM-CRC (nD 11) primary CRC (nD 12)
Gender (female/male) 16 / 37 4 / 7 5 / 7
Age (years) 66.3 § 3.3 56.9 § 3.8 63.4 § 3.4
Stage of disease (TNM) Stage IV n D 53 Stage IV n D 11 Stage I n D 3, Stage II n D 4, Stage III n D 4, Stage IV
nD 1
Tumor MMR status MMR-deﬁcient n D 2, MMR-proﬁcient
n D 51
MMR-deﬁcient n D 0, MMR-proﬁcient
n D 11
MMR-deﬁcient nD 3, MMR-proﬁcient
nD 9
Abbreviations: CRC, colorectal cancer; LM-CRC, liver metastasis of CRC; PM-CRC, peritoneal metastasis of CRC; TNM, tumor-node-metastasis; MMR, mismatch repair.
Mean § standard error of the mean.
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immunological tumor control in primary as well as metasta-
sized CRC,42 is more favorable in CRC metastases com-
pared to primary CRC. In addition, the increased
expression of PD-1 on TIL suggests that TIL of LM-CRC
may be more sensitive to blockade of the PD-1/PD-L1 path-
way than TIL of primary CRC.
Figure 1. Comparison of immune inﬁltrates and inhibitory molecule expression among MMR-proﬁcient liver metastases (LM), peritoneal metastases (PM) and primary
CRC. (A) The frequencies of CD8C CTL, CD4CFoxp3¡ Th and CD4CFoxp3C Treg within CD3C TIL from LM-CRC, primary CRC and PM-CRC. (B) The frequencies of inhibitory
receptor positive cells within CD8C CTL, Th and Treg in LM-CRC, primary CRC and PM-CRC. (C) The frequencies of B cells, mDC and monocytes (Mono) within CD45C cells
from LM-CRC, primary CRC and PM-CRC. (D) The frequencies of inhibitory ligand positive cells within tumor-inﬁltrating B cells, mDC and monocytes from LM-CRC, primary
CRC and PM-CRC. Values of individual patients are shown, and lines depict medians. Differences were analyzed by unpaired t test or Mann-Whitney test; p < 0.05, p <
0.01, p < 0.001.
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Figure 2. Expression of inhibitory receptors on CD8C CTL, CD4C Th and CD4C Treg in the tumor, TFL and blood of MMR-proﬁcient LM-CRC. PBMC and leukocytes isolated
from LM-CRC tumors and TFL were stained with antibodies against PD-1, LAG3, TIM3 and CTLA4. (A) (B) Representative dot plots of inhibitory receptor expression on (A)
CD3CCD8C CTL and (B) CD3CCD4CFoxp3¡ Th in the tumor, TFL and blood; the gates were made according to appropriate isotype controls. (C) (D) (E) The frequencies of
inhibitory receptor positive cells within (C) CD8C CTL, (D) CD4CFoxp3¡ Th and (E) CD4CFoxp3C Treg in the tumor, TFL and blood. Values of individual patients are shown,
and lines depict medians. Differences were analyzed by paired t test or Wilcoxon matched pairs test; p < 0.05, p < 0.01, p< 0.001.
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Figure 3. Intra-tumoral antigen-presenting cells of MMR-proﬁcient LM-CRC express inhibitory ligands. Expression of inhibitory ligands PD-L1, galectin 9 (GAL-9), MHC-II,
CD86 and CD80 was measured by ﬂow cytometry. (A) The frequencies of CD19C B cells, BDCA1CCD19¡ mDC and CD14C monocytes (Mono) within CD45C cells derived
from tumors, TFL and blood. Values of individual patients are presented, lines depict medians. (B) Representative histograms of inhibitory ligand stainings and isotype
controls on tumor-inﬁltrating mDC, monocytes and B cells. (C) The frequencies of inhibitory ligand positive cells within tumor-inﬁltrating B cells, mDC and monocytes in
individual patients are presented; lines depict medians. (D) The median ﬂuorescence intensities (MFI) of inhibitory ligands on B cells, mDC and monocytes derived from
tumors, TFL and blood of LM-CRC patients. Values of individual patients are shown, and lines depict medians. Differences were analyzed by paired t test or Wilcoxon
matched pairs test; p < 0.05, p < 0.01, p < 0.001.
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Elevated expression of inhibitory receptors on CD8C
cytotoxic T cells, CD4C T helper cells and regulatory T cells
in MMR-proﬁcient LM-CRC tumors
We isolated leukocytes from surgically resected metastatic
liver tumors, TFL and blood of LM-CRC patients, and com-
pared the expression levels of ﬁve inhibitory receptors (PD-
1, TIM3, LAG3, CTLA4 and BTLA) on CD8C CTL,
CD4CFoxp3¡ Th and CD4CFoxp3C Treg. When compared
to TFL and blood, signiﬁcantly higher proportions of CD8C
CTL, Th and Treg in TIL expressed PD-1 and TIM-3. In
addition, TIL contained higher frequencies of CTLA4C CTL
and CTLA4C Th, while LAG3 was overexpressed on CD8C
CTL in TIL when compared to TFL and blood (Fig. 2).
Interestingly, the highest expression of CTLA4, which is
functionally involved in the suppressive capacity of Treg,43
and also of PD-1 and TIM3 was found on tumor-inﬁltrating
Treg. In contrast, frequencies of BTLAC cells in intra-
Figure 4. Tumor-inﬁltrating T cells expressing inhibitory receptors show increased expression of activation markers. TIL from MMR-proﬁcient LM-CRC were stained ex vivo
with antibodies against surface activation markers HLA-DR and CD69. (A) (B) The frequencies of HLA-DRC or CD69C cells in (A) CD8C CTL and (B) CD4C Th that do or do
not express PD-1, TIM3, LAG3, or CTLA4 are presented (n D 9–11). Lines show medians, whiskers depict minimum to maximum. Differences were analyzed by paired t
test or Wilcoxon matched pairs test. (C) (D) TIL from MMR-proﬁcient LM-CRC were stimulated with PMA and ionomycin at 37C for ﬁve hours, in the presence of protein
transport inhibitor brefeldin for the last four hours, followed by intracellular cytokine staining. The frequencies of cytokine-producing cells in (C) CD8C CTL and (D) CD4C
Th that do or do not express inhibitory receptors are presented (n D 7–12). Lines show medians, whiskers depict Min to Max, boxes indicate the 25th to 75th percentiles.
Differences were analyzed by paired t test or Wilcoxon matched pairs test; p < 0.05, p < 0.01, p< 0.001.
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tumoral T cells were low, and they did not differ signiﬁ-
cantly from those in TFL and blood (Supplementary
Fig. S3). Therefore, we focused on the other four receptors
in the rest of this study. To investigate whether the expres-
sion of inhibitory receptors on circulating T cells had a
relation with the expression on intra-tumoral T cells, we
performed correlation analysis, as illustrated in Supplemen-
tary Fig. S4. There were signiﬁcant positive correlations
between the frequencies of PD-1C CTL and PD-1C Treg in
the tumor and those in the blood, between the frequency of
LAG3C Th in the tumor and that in the blood, and between
the frequencies of CTLA4C Th and CTLA4C Treg in the
tumor and those in the blood. These results indicate that
the expression of inhibitory receptors on circulating T cells
partly reﬂects their expression on intra-tumoral T cells.
Intra-tumoral antigen-presenting cells express inhibitory
ligands
To study the expression of inhibitory ligands PD-L1, galec-
tin 9, MHC-II molecules, CD86 and CD80 on APC in LM-
CRC tissues, we measured these molecules by ﬂow cytome-
try. Three major APC subsets BDCA-1CCD19¡ mDC,
CD14C monocytes and CD19C B cells were found in all
tumors. The frequency of B cells was higher in tumors than
in TFL, and the frequency of mDC was higher in tumors
and TFL than in the blood, whereas the frequency of mono-
cytes was lower in tumors than in the blood (Fig. 3A). The
three different tumor-inﬁltrating APC populations expressed
the ﬁve ligands at different levels and considerable varia-
tions between individual patients were observed (Fig. 3B,
C). Intra-tumoral mDC and monocytes contained higher
proportions of PD-L1C and MHC-IIC cells than intra-
tumoral B cells. The median ﬂuorescence intensities of ﬁve
ligands in APC subsets in the tumor, TFL and blood are
presented in Fig. 3D, showing that the expression of inhibi-
tory ligands is generally not increased on tumor-inﬁltrating
APC compared to APC in TFL. Together, the abovemen-
tioned data suggest that inhibitory interactions between T
cells and APC in MMR-proﬁcient LM-CRC are possible.
Intra-tumoral T cells expressing inhibitory receptors show
increased levels of activation markers
Considering that increased expression of inhibitory receptors
on T cells can be induced by recent activation, or by chronic
stimulation that may lead to T cell dysfunctionality, we exam-
ined the ex vivo activation status and in vitro effector cytokine
production of effector T cells derived from MMR-proﬁcient
LM-CRC. First we compared the expression of activation
markers HLA-DR and CD69 on intra-tumoral T cells that do
or do not express inhibitory receptors. Interestingly, PD-1C,
TIM3C, LAG3C or CTLA4C CTL and Th showed a more acti-
vated status than PD-1¡, TIM3¡, LAG3¡ or CTLA4¡ CTL and
Th, respectively (Fig. 4A, B). Subsequently, we assessed effector
cytokine production of tumor-derived T cells after short-term
PMA and ionomycin stimulation. Despite the activated status,
the frequencies of inhibitory receptor positive CTL and Th cells
that produced IFN-g and TNF-a were reduced or similar to
those in the respective receptor negative T cells (Fig. 4C, D).
Interestingly, LAG3C CTL and Th cells did not show reduction
in cytokine production. Because among all studied inhibitory
receptors, tumor-inﬁltrating CTL and Th showed the highest
expression of PD-1 (Fig. 2C, D), we analyzed co-expression of
PD-1 and the other three receptors. Co-expression of PD-1 and
either TIM3, LAG3 or CTLA4 was found, especially in CD8C
CTL, but expression of TIM3, LAG3 or CTLA4 without PD-1
was also observed (Supplementary Fig. S5). Similar to single
receptor positive CTL and Th, double receptor positive CTL
and Th showed reduced or comparable frequencies of IFN-g
and TNF-a producing cells to double receptor negative cells,
while LAG3CPD-1C CTL and Th did not show signiﬁcant
reduction in cytokine production (Fig. 4C, D). These data dem-
onstrate that in general intra-tumoral T cells that express inhib-
itory receptors do not produce more effector cytokines, despite
the activated status.
Antibody blockade of LAG3 or PD-L1 boosts ex vivo
proliferation and effector cytokine production of T cells
derived from MMR-proﬁcient LM-CRC
Because PD-1, TIM3, LAG3 and CTLA4 are upregulated on T
cells in MMR-proﬁcient LM-CRC tumors, we tested whether
blockade of the PD-1/PD-L1, TIM3/galectin 9, LAG3/MHC-II
or CTLA4/CD80/CD86 pathways could enhance the effector
functions of tumor-derived T cells. We stimulated CFSE-
labeled total tumor-inﬁltrating mononuclear leukocytes with
CD3/CD28 beads, in the presence or absence of antagonistic
antibodies against human PD-L1, TIM3, LAG3, CTLA4 or iso-
type controls (mIgG1 or mIgG2 a). After four days of culture,
T cell proliferation was measured by ﬂow cytometry (Fig. 5A),
and effector cytokine secretion in the culture supernatants was
quantiﬁed by enzyme-linked immunosorbent assay. Fig. 5B
illustrates that the baseline proliferation of CD8C and CD4C T
cells derived from tumors was signiﬁcantly lower than that of T
cells from the blood of the same patients, indicating the prolif-
erative function of intra-tumoral T cells is impaired compared
to circulating T cells of patients with MMR-proﬁcient LM-
CRC. Interestingly, treatment with anti-LAG3 antibody or
anti-PD-L1 antibody signiﬁcantly increased the proliferation of
both CD8C and CD4C TIL compared with the control condi-
tion without antagonistic antibody (Fig. 5C). These two anti-
bodies also signiﬁcantly increased IFN-g and TNF-a secretion
(Fig. 5D).
Antibody blockade of LAG3 or PD-L1 boosts ex vivo
responses of T cells derived from MMR-proﬁcient LM-CRC
to autologous tumor antigens
To investigate whether blockade of the aforementioned inhibi-
tory pathways can enhance tumor-speciﬁc anti-tumor T cell
responses, we stimulated CFSE-labeled total tumor-inﬁltrating
mononuclear leukocytes with autologous blood-derived mDC
preloaded with autologous tumor lysates, in the presence or
absence of antagonistic antibodies, and measured CD8C and
CD4C T cell proliferation after six days. Increased TIL prolifera-
tion against mDC loaded with tumor lysates compared with
mDC without tissue lysates was observed in all ﬁve tested
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patients, while loading of mDC with normal liver lysates did not
increase or minimally increased TIL proliferative responses
(Fig. 6A, C). Addition of anti-PD-L1 antibody enhanced
proliferative responses of TIL in all four tested patients, while
treatment with anti-LAG3 antibody increased both CD8C and
CD4C TIL proliferation in four out of ﬁve patients. In three out
Figure 5. Antibody blockade of LAG3 or PD-L1 boosts ex vivo proliferation and cytokine production of intra-tumoral T cells from MMR-proﬁcient LM-CRC in response to
polyclonal stimuli. CFSE-labeled TIL from LM-CRC patients were stimulated with CD3/CD28 beads for four days, in the presence or absence of 10 mg/ml antagonistic anti-
bodies. (A) Representative dot plots of CD3CCD8C and CD3CCD4C TIL proliferation in response to CD3/CD28 beads (a-CD3/CD28) in the presence or absence of antagonis-
tic antibodies (a-) or isotype controls (iso ctrl). Dotplots indicated by “TIL” show proliferative responses in the absence of CD3/CD28 beads. In all other conditions, CD3/
CD28 beads were added. (B) The percentages of proliferating cells (CFSE-low) within CD8C and CD4C T cells derived from the tumor or blood in response to CD3/CD28
beads without addition of any antagonistic antibody. Values of individual patients are presented. (C) Effects of antibody blockade of inhibitory interactions on CD8C and
CD4C TIL proliferation (n D 7-9). Because the proliferative responses differed between patients, the results are reported as relative proliferation in the presence of anti-
bodies compared to baseline proliferation, which was calculated by dividing the percentages of proliferating (CFSE-low) T cells in the presence of antagonistic antibody
or isotype control antibody by the percentages in the control condition with only CD3/CD28 beads. Values are depicted as means with standard error of the mean. (D)
IFN-g and TNF-a accumulation in culture supernatants was quantiﬁed at day four by enzyme-linked immunosorbent assay. Values are depicted as medians with interquar-
tile range (n D 10-11). Differences were analyzed by paired t test or Wilcoxon matched pairs test; p< 0.05, p < 0.01.
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Figure 6. Antibody blockade of LAG3 or PD-L1 boosts ex vivo responses of intra-tumoral T cells from MMR-proﬁcient LM-CRC to autologous tumor antigens. Blood mDC
loaded with autologous tumor lysates were used to stimulate CFSE-labeled TIL, in the presence or absence of 10 mg/mL antagonistic antibodies. After six days T cell prolif-
eration and intracellular cytokine production were analyzed after re-stimulation with PMA and ionomycin. (A) (B) Representative dot plots of T cell proliferation, IFN-g and
TNF-a expression in CD3CCD8C and CD3CCD4C TIL, in response to autologous mDC pre-loaded with tumor lysates (TILCmDCCtumor lysate), in the presence or absence
of antagonistic antibodies (a-). TIL responses to mDC that were not pre-loaded with tumor lysates (TILCmDC) served as controls to determine non-antigen-speciﬁc TIL
proliferation and cytokine production. (C) (D) (E) Collective data of ﬁve patients tested. Each line and each color represent one patient. The results are reported as net
tumor-speciﬁc responses, calculated by subtracting the percentages of proliferating (CFSE-low) T cells or IFN-gC or TNF-aC proliferating T cells in the control condition
(mDC without tissue lysates) from the percentages in the conditions with tumor lysates (TL) in the absence or presence of antagonistic antibody. In two experiments an
additional control was included, in which TIL were stimulated with blood mDC pre-loaded with normal liver lysates (NL), which did not lead to increased TIL responses.
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of four patients anti-LAG3 antibody boosted CD8C and/or
CD4C TIL responses to higher levels than anti-PD-L1 antibody
(Fig. 6A, C). After ﬁve hours of restimulation, intracellular
expression of IFN-g and TNF-a in proliferating T cells was ana-
lyzed, and was found to be enhanced by both anti-LAG3 and
anti-PD-L1 antibodies in most patients (Fig. 6B, D, E). Like in
CD3/CD28 stimulations, anti-TIM3 and anti-CTLA4 antibodies
boosted TIL responses less strongly and also in less patients.
Higher LAG3 expression on intra-tumoral CD8C T cells is
associated with longer progression-free survival of
patients with MMR-proﬁcient LM-CRC
In a subset of patients, we could analyze associations between
the frequencies of inhibitory receptor positive TIL and patient
progression-free survival after the LM-CRC resection. In sur-
vival analysis higher expression of LAG3 on CD8C TIL, CD4C
Th and Treg was associated with longer time to recurrence
(Fig. 7), whereas higher expression of PD-1 or TIM3 on CD8C
TIL was associated with shorter time to recurrence (data not
shown). In multivariable analysis only LAG3 expression on
CD8C TIL was demonstrated to be an independent predictor of
progression-free survival (Table 2), which supports its func-
tional relevance to anti-cancer immunity in TIL of LM-CRC.
We hypothesize that LAG3CCD8C TIL may be highly activated
T cells (Fig. 4A) stimulated by tumor antigens, but subse-
quently inhibited by increased and continuous expression of
LAG3 and interaction with its ligands on APC and tumor cells,
yet with preserved effector functions (Fig. 4C), which may con-
trol tumor growth. Because the sample size is small, these
results need conformation in an independent study. In one
fourth of the patients we only have data of LAG3 expression on
CD8C TIL but not on CD4C Th or Treg, so we did not include
the latter T cell subsets in the multivariable analysis. The death
events were too few to analyze overall survival of LM-CRC
patients.
Discussion
Checkpoint inhibitors have recently emerged as attractive treat-
ments for several types of solid cancers. However, PD-1 and
PD-L1 blocking antibodies were proven unsuccessful in CRC,
with the exception of MMR-deﬁcient CRC.23-25,27,28 The ﬁrst
aim of this study was to investigate whether the composition of
the immune inﬁltrates and the intra-tumoral expression levels
of inhibitory molecules in CRC metastases in the liver environ-
ment differ from those in primary CRC tumors and metastases
outside the liver, which would suggest potential differences in
sensitivity to checkpoint inhibitors among CRC tumors at dif-
ferent anatomical locations. The second objective was to deter-
mine whether targeting of inhibitory checkpoint pathways by
antagonistic antibodies can enhance the functionality and anti-
tumor responses of tumor-inﬁltrating T cells in LM-CRC.
Because the incidence of MMR deﬁciency in LM-CRC is low,
we focused on MMR-proﬁcient tumors.
This study is the ﬁrst to investigate the expression levels of
inhibitory receptors on TIL in LM-CRC. Similar to what we
reported in hepatocellular carcinoma,44 intra-tumoral CD8C
CTL and CD4C Th in MMR-proﬁcient LM-CRC displayed
increased expression of PD-1, TIM3, CTLA4 and/or LAG3
compared to their counterparts in TFL and blood. In addition,
we found selectively enhanced expression of PD-1 and TIM3
on intra-tumoral Treg (Fig. 2C-E). The elevated frequencies of
inhibitory receptor positive cells in TIL together with the
expression of their ligands on tumor-inﬁltrating APC (Fig. 3B-
D) suggest that these inhibitory checkpoint pathways may be
involved in intra-tumoral suppression of T cells in MMR-proﬁ-
cient LM-CRC.
Figure 7. Kaplan-Meier curves of progression-free survival (time to recurrence) in
relation to LAG3 expression on intra-tumoral T cells in MMR-proﬁcient LM-CRC.
The cutoff values to divide the patients into two groups are the median percen-
tages of LAG3C cells in tumor-inﬁltrating CD8C CTL, CD4CFoxp3¡ Th or
CD4CFoxp3C Treg cells. For determination of the p values the Breslow test was
used.
Table 2. Multivariable Cox proportional Hazard regression analysis of progression-
free survival of patients with MMR-proﬁcient LM-CRC.
95% CI for HR
Variables P value HR Lower Upper
PD-1 on CD8C TIL .160 2.418 .706 8.283
TIM3 on CD8C TIL .774 1.183 .375 3.732
LAG3 on CD8C TIL .032 .351 .135 .912
Abbreviations: TIL, tumor-inﬁltrating lymphocytes; HR, hazard ratio; CI, conﬁdence
interval.
The hazard ratio is interpreted as the chance of recurrence occurring in the “>
median” group to the chance of recurrence occurring in the “< median” group.
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Interestingly, we observed higher expression of PD-1 and/or
TIM3 on CD8C CTL and Treg in LM-CRC than in primary
CRC, while expression of LAG3, TIM3 and/or PD-1 on CD8C
CTL, Th and Treg was higher in LM-CRC than in PM-CRC
(Fig. 1B). We hypothesize that these differences are due to the
unique tolerogenic properties of the liver environment, which
induces expression of inhibitory receptors on hepatic T cells
both in diseased and healthy conditions.37,38 Furthermore, we
found increased proportions of CD8C CTL in LM-CRC and
PM-CRC compared with primary CRC (Fig. 1A). The observed
differences between MMR-proﬁcient LM-CRC and MMR-pro-
ﬁcient primary CRC are to some extent reminiscent of
those found between MMR-deﬁcient primary CRC and MMR-
proﬁcient primary CRC by Llosa et al.31 They demonstrated
that MMR-deﬁcient primary CRC displayed higher inﬁltration
with CD8C CTL as well as upregulated expression of PD-1,
PD-L1, CTLA4 and LAG3 compared to MMR-proﬁcient pri-
mary CRC, and suggested that these differences contributed to
the enhanced clinical responsiveness to anti-PD-1 therapy of
microsatellite instable CRC compared with microsatellite stable
CRC.31 In addition, we found that LM-CRC contained
increased frequencies of professional APC subsets (mDC and
monocytes) (Fig. 1C), which may result in improved presenta-
tion of tumor antigens to intra-tumoral T cells as well as more
PD-L1 and MHC-II expression in LM-CRC compared with pri-
mary CRC, because in LM-CRC mDC and monocytes
expressed more PD-L1 and MHC-II than B cells (Fig. 3C).
Hierarchical clustering analysis showed that the immune phe-
notypical data of most LM-CRC tumors clustered together as
did the data of most primary CRC tumors (Supplementary
Fig. S2). These data conﬁrm those of Halama et al., who dem-
onstrated similar heterogeneity in composition of immune
inﬁltrates between paired primary CRC tumors and liver
metastases derived from the same patients.35 We extracted and
statistically analyzed their paired data of primary CRC and
LM-CRC from 16 patients and found a higher CD8C cell den-
sity in LM-CRC than in primary CRC (Supplementary Fig. S6).
Moreover, discrepancies in somatic mutations, copy number
alterations, genetic and epigenetic molecular alterations
between primary CRC tumors and matched liver metastases
were revealed in up to a half of the cases, which may lead to
higher mutational load and thereby more neo-epitopes in LM-
CRC.45-48 Together, these ﬁndings indicate major differences
between liver metastases and primary CRC as well as peritoneal
metastases, including differences in immune cell inﬁltration
and inhibitory molecule expression, which may be at least
partly induced by the liver environment. We therefore suggest
that TIL of MMR-proﬁcient LM-CRC may be more sensitive to
PD-1/PD-L1 blockade and other checkpoint inhibitors than
TIL of MMR-proﬁcient primary CRC and CRC metastases at
other anatomical locations. Nevertheless, to precisely compare
the effects of checkpoint inhibitors on TIL of primary CRC and
LM-CRC, experiments with TIL from paired tissues might be
needed but were unfortunately not available in the current
study.
To determine whether TIL expressing inhibitory receptors
represent T cells that are recently activated upon recognition of
tumor antigens, or are dysfunctional due to chronic antigenic
stimulation, we studied their ex vivo activation status and in
vitro effector cytokine production. Similar to what we reported
in hepatocellular carcinoma,44 intra-tumoral CD4C Th and
CD8C CTL expressing any of the four inhibitory receptors
showed a more activated status but produced reduced or simi-
lar levels of effector cytokines than their counterparts not
expressing the corresponding inhibitory receptor (Fig. 4). How-
ever, in our ex vivo cultures, tumor cells that may express inhib-
itory ligands are lacking, so the TIL might be less functional in
vivo and need checkpoint inhibitors. Nevertheless, proliferative
responses of tumor-derived T cells to CD3/CD28 stimulation
were lower than those of circulating T cells (Fig. 5B). Consis-
tent with what others reported on IFN-g production by CD8C
TIL in primary CRC patients,49,50 our results demonstrate a
certain degree of dysfunctionality of intra-tumoral CD4C Th
and CD8C CTL in MMR-proﬁcient LM-CRC, which may be at
least partly due to inhibitory checkpoint interactions between T
cells and APC subsets in the TIL cultures, but not complete
dysfunctionality.
This study is also the ﬁrst to investigate the effects of anti-
body blockade of four inhibitory checkpoint pathways on
responses of TIL isolated from MMR-proﬁcient LM-CRC. In
both polyclonal T cell activation and tumor-speciﬁc TIL stimu-
lation assays, increased proliferation of TIL and increased pro-
duction of effector cytokines were observed upon the addition
of anti-LAG3 antibody or anti-PD-L1 antibody (Fig. 5 and
Fig. 6) In some patients ex vivo anti-tumor responses of TIL
were more robustly enhanced by anti-LAG3 antibody than by
anti-PD-L1 antibody (Fig. 6), suggesting that LAG3 might be
the most promising target for immunotherapy of LM-CRC
among all four checkpoint pathways tested in this study. How-
ever, these data need conﬁrmation using TIL from a larger
number of patients. The superiority of LAG3 blockade com-
pared to PD-L1 blockade was more seen in tumor antigen-spe-
ciﬁc stimulation than in polyclonal stimulation. We
hypothesize that the small proportion of LAG3C TIL is strongly
enriched with tumor antigen-reactive T cells, which are known
to constitute only a small proportion of all tumor-inﬁltrating T
cells. In addition, we propose that PD-1 is expressed on a larger
fraction of TIL which contains more non-tumor antigen-spe-
ciﬁc T cells. Although TIM3 blockade was reported to reduce T
cell apoptosis and inhibit tumor growth in a mouse CT26 colon
tumor model,51 little effect was observed in our experiments
using TIL derived from human LM-CRC. This result also con-
trasts to our recent observation that ex vivo responses of TIL
isolated from hepatocellular carcinomas can be invigorated by
TIM3 blockade.44 This difference may relate to the lower
expression of galectin 9 on APC subsets in LM-CRC compared
to hepatocellular carcinomas.
Because we were interested in the net effects of checkpoint
inhibitors on TIL responses in a context that reﬂected the LM-
CRC tumor microenvironment as much as possible, we used
total tumor-inﬁltrating mononuclear leukocytes in our func-
tional assays, which contained both T cells expressing inhibi-
tory receptors and APC expressing inhibitory ligands. As a
consequence, tumor-inﬁltrating Treg,40,41 type 1 regulatory T
cells52 and probably other types of immune suppressor cells
were also present in these assays. Therefore, the reported func-
tional effects of checkpoint inhibitors on effector T cells in
these assays may be partly indirect, mediated by effects of these
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antibodies on suppressor cells. The effects of checkpoint inhibi-
tor on effector T cells in our assays might even be counteracted
by its effects on suppressor cells. We found that half of Treg in
LM-CRC tumors expressed PD-1, and blocking PD-1/PD-L1
interaction was shown to enhance the suppressive function of
Treg isolated from liver tissues of patients with chronic hepati-
tis C infection.53
Interestingly, higher expression of LAG3 on CD8C TIL was
associated with longer time to recurrence of patients with LM-
CRC. We hypothesize that LAG3CCD8C TIL are cells which
have recently been activated (Fig. 4A) by recognition of anti-
gens in the tumor, and upregulate LAG3 expression in
response to activation but still have functional capacity to
exert effector functions and delay tumor growth (Fig. 4C).
LAG3 expression is upregulated on T cells after activation
and differentiation,54,55 and intra-tumoral T cells that recog-
nize tumor antigens are characterized by expression of LAG3
and other inhibitory receptors.56 Although chronic tumor
antigen stimulation in the tumor microenvironment can
induce T cell exhaustion with simultaneous induction of high
expression of multiple inhibitory receptors, this does not
mean that all CD8C TIL which express one or more inhibitory
receptors at any level are functionally exhausted. Indeed, a
recent mouse study showed that tumor antigen-speciﬁc TIL
which expressed LAG3 or PD-1 produced IFN-g in situ and
had cytolytic potential.57 Likewise, in the current study we
observed that LAG3CCD8C TIL in LM-CRC were not func-
tionally impaired (Fig. 4C). Nevertheless, they could be func-
tionally invigorated upon antibody blockade of LAG3 (Fig. 5
and Fig. 6), indicating that interaction of LAG3 with its
ligands serves as an extrinsic mechanism in the tumor micro-
environment which inhibits their functionality.
Our study has several limitations:1 Due to the ﬁnite numbers
of isolated TIL, the tumor-speciﬁc stimulation assay could only
be performed in a limited number of LM-CRC patients (Sup-
plementary Table S1), neither could all the conditions be tested
in every functional assay, nor could the relation between the
expression of inhibitory molecules on TIL and the effects of
checkpoint inhibitors on TIL responses be well analyzed.2 We
could not study paired LM-CRC, primary CRC and PM-CRC
tumors from the same patients because primary and metastatic
CRC tumors were resected at different time points and in dif-
ferent hospitals.3 MMR-deﬁcient tumors could not be studied
well, because we received fresh tissues from only a few MMR-
deﬁcient tumors during our study.
In conclusion, increased frequencies of CD8C CTL, mDC
and monocytes as well as increased inhibitory receptor expres-
sion on intra-tumoral T cells in MMR-proﬁcient LM-CRC sug-
gest that TIL of MMR-proﬁcient LM-CRC may be more
sensitive to immune checkpoint inhibitors than TIL of MMR-
proﬁcient primary CRC. Blockade of LAG3 and PD-L1 can
both enhance ex vivo functions of tumor-inﬁltrating T cells
from MMR-proﬁcient LM-CRC. Therefore, these two inhibi-
tory pathways may be potential immunotherapeutic targets for
the most prevalent metastatic liver cancer, despite the lack of
MMR deﬁciency. Clinical studies focusing on responses of LM-
CRC to anti-LAG3 and combination with anti-PD-L1 or anti-
PD-1 antibodies12,58 are required to conclude whether this
prediction based on our preclinical study is correct.
Patients and methods
Patients and specimens
Fifty three patients who were eligible for surgical resection of
LM-CRC were enrolled in the study from November 2013 to
March 2017. Another twelve patients who received surgical
resection of primary CRC and another eleven patients whose
PM-CRC were surgically resected before hyperthermic intra-
peritoneal chemotherapy were enrolled in the study from
February 2016 to December 2016. Fresh tissue samples from
hepatic tumors, tumor-free liver tissues as distant as possible
from the tumor (minimum 1 cm distance), colorectal tumors
and peritoneal tumors were obtained. Peripheral blood from
LM-CRC patients was also collected on the day of resection.
None of the patients received chemotherapy or immunosup-
pressive therapy at least three months before surgery. The clini-
cal characteristics of the patients are summarized in Table 1.
The study was approved by the local ethics committee, and
signed informed consent from all patients was obtained before
tissue and blood donation.
Cell preparation
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll density gradient centrifugation. Single cell suspensions
from tumors and tumor-free liver were obtained by tissue
digestion. Brieﬂy, fresh tissues were ﬁrst cut into small pieces
and then digested with 0.125 mg/mL collagenase IV (Sigma-
Aldrich, St. Louis, MO) and 0.2 mg/mL DNAse I (Roche, Indi-
anapolis, IN) in Hanks’ Balanced Salt solution with Ca2C and
Mg2C (Sigma, Zwijndrecht, The Netherlands) for 30 minutes at
37C with interrupted gently swirling. Cell suspensions were
ﬁltered through 100 mm pore cell strainers (BD Biosciences,
Erembodegem, Belgium) and mononuclear leukocytes were
obtained by Ficoll density gradient centrifugation. Viability was
determined by trypan blue exclusion.
Flow cytometric analysis
Fresh peripheral blood mononuclear cells (PBMC) and leuko-
cytes isolated from tissues were analyzed for expression of sur-
face and intracellular markers using speciﬁc antibodies
(Supplementary Table S2). Cell surface staining with ﬂuoro-
chrome-conjugated antibodies was performed in the dark at
4C for 30 minutes, then cells were washed and resuspended in
phosphate buffered saline with 0.2 mM EDTA and 0.5% human
serum. For Foxp3 and CTLA4 staining, cells were ﬁxed and
permeabilized using the Foxp3 staining buffer set (eBioscience,
Vienna, Austria). For intracellular cytokine staining, cells were
stimulated with 40 ng/mL PMA (Sigma, Zwijndrecht,
The Netherlands) and 1 mg/mL ionomycin (Sigma) at 37C for
ﬁve hours in the presence of 5 mg/mL brefeldin (Sigma) for the
last four hours, followed by staining of IFN-g and TNF-a upon
ﬁxation and permeabilization using the Foxp3 staining buffer
set. Dead cells were excluded by using a LIVE/DEAD ﬁxable
dead cell stain kit with aqua ﬂuorescent reactive dye (Invitro-
gen, Paisley, UK). Cells were measured using a FACS Canto II
ﬂow cytometer (BD Biosciences, San Diego, USA) and analyzed
using FlowJo software (version 10.0, LLC). Appropriate isotype
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control antibodies were used for gating purposes (Supplemen-
tary Table S2).
Ex vivo polyclonal T cell activation assay
All LM-CRC cell cultures were performed in complete medium
RPMI 1640 (Lonza, Breda, The Netherlands) supplemented
with 10% human AB serum (Invitrogen), 2 mM L-glutamine
(Invitrogen), 50 mM Hepes Buffer (Lonza), 1% penicillin-strep-
tomycin (Life Technologies), 5 mM Sodium Pyruvate (Gibco)
and 1% minimum essential medium non-essential amino
acids), at 37C. TIL and PBMC from LM-CRC were labeled
with 0.1 mM carboxyﬂuorescein diacetate succinimidyl ester
(CFSE, Invitrogen); afterwards 105 TIL or PBMC were cultured
in 200 ml complete medium in each well of a 96-well round-
bottom culture plate and stimulated with anti-human CD3/
CD28 dynabeads (Gibco-Life Technologies AS, Norway) at a
cell: bead ratio of 10:1, in the presence or absence of 10 mg/ml
antagonistic monoclonal antibodies against human PD-L1
(clone 5H1, kindly provided by Dr. Haidong Dong, Mayo
Clinic College of Medicine,59) TIM3 (clone F38-2E2, Biolegend,
San Diego, USA,60,61) LAG3 (clone 17B4, AdipoGen, Liestal,
Switzerland62) or CTLA4 (clone BNI3, Beckman Coulter,
Marseille, France,63) or isotype-matched control antibodies
(mIgG1 and mIgG2 a, Biolegend, London, UK). In preliminary
experiments a cell: bead ratio of 10:1 was established to provide
sub-optimal stimulation of T cell proliferation. After four days,
culture supernatant was collected and frozen at -20C until
secretion of IFN-g and TNF-a was quantiﬁed by enzyme-
linked immunosorbent assay (ELISA, Ready-SET-Go!, eBio-
science). CFSE-labeled cells were harvested and stained with
CD8, CD4 and CD3 antibodies. Dead cells were excluded by
using the LIVE/DEAD ﬁxable dead cell stain kit with aqua ﬂuo-
rescent reactive dye, and T cell proliferation was determined
based on CFSE dilution by ﬂow cytometric analysis.
Ex vivo tumor-speciﬁc T cell stimulation assay
Tumor lysates and normal liver lysates were generated from a
small piece of freshly resected metastatic liver tumor or TFL by
ﬁve cycles of freezing and thawing in phosphate buffered saline,
followed by ﬁltration (0.2 mm syringe ﬁlter), as previously
described.40,41 Myeloid dendritic cells (mDC) were isolated
from patient autologous PBMC by depletion of CD19C B cells
followed by positive selection for BDCA-1 (BDCA-1 DC isola-
tion kit, Miltenyi Biotec). mDC were cultured overnight with
or without 20 mg/mL autologous tumor lysates or normal liver
lysates, in the presence of 10 ng/mL granulocyte-macrophage
colony-stimulating factor (Miltenyi Biotec) and 0.5 mg/mL pol-
yinosinic: polycytidylic acid (InvivoGen, San Diego, CA).
Simultaneously TIL isolated from LM-CRC were kept at 4C in
complete medium overnight. Thereafter TIL were labeled with
0.1 mM carboxyﬂuorescein diacetate succinimidyl ester (CFSE,
Invitrogen), and 105 TIL were co-cultured with autologous
mDC preloaded with or without tumor lysates or normal liver
lysates at an mDC: TIL ratio of 1:5, in the presence or absence
of 10 mg/ml antagonistic monoclonal antibodies against human
PD-L1 (clone 5H1, kindly provided by Dr. Haidong Dong,
Mayo Clinic College of Medicine,59) TIM3 (clone F38-2E2,
Biolegend, San Diego, USA,44) LAG3 (clone 17B4, AdipoGen,
Liestal, Switzerland44) or CTLA4 (clone BNI3, Beckman Coul-
ter, Marseille, France,63) in 200 ml complete medium in each
well of a 96-well round-bottom culture plate. After six days,
cells were restimulated with PMA (40 ng/mL) and ionomycin
(1 mg/mL) for ﬁve hours in the presence of 5 mg/mL brefeldin
for the last four hours. Cells were then stained with CD8, CD4
and CD3 antibodies, followed by intracellular staining of IFN-g
and TNF-a upon ﬁxation and permeabilization according to
the manufacturer’s instructions (eBioscience A&B ﬁxation/per-
meabilization kit). Dead cells were excluded by using the LIVE/
DEAD ﬁxable dead cell stain kit with aqua ﬂuorescent reactive
dye, and T cell proliferation was determined based on CFSE
dilution by ﬂow cytometric analysis.
Determination of mismatch repair status
by immunohistochemistry
Immunostainings were performed on formalin-ﬁxed parafﬁn-
embedded whole tissue sections (4 mm thick) using the Bench-
mark Ultra autoimmunostainer (Ventana Medical Systems Inc,
Roche Group, Tucson, USA) according to the manufacturer’s
protocols and instructions. Brieﬂy, deparafﬁnization was fol-
lowed by heat-induced epitope retrieval in Ultra CC1 pre-
diluted buffer for 48–60 minutes at 100C. Primary antibodies
anti-MLH1 (Novocastra; Leica Microsystems B.V., Amsterdam,
The Netherlands; clone ES05; dilution 1:75), anti-PMS2 (Cell
Marque, Rocklin, USA; clone EPR3947, ready to use), anti-
MSH2 (Cell Marque, clone G219-1129; ready to use) and anti-
MSH6 (Dako, Glosturp, Denmark; clone EP49; dilution 1:75)
were applied and followed by incubation (from 40 minutes to
1 hour and 32 minutes). Upon antibody incubation Ventana
standard signal ampliﬁcation was performed, followed by ultra-
Wash counter-staining with one drop of Hematoxylin (for
20 minutes) and one drop of bluing reagent (for 4 minutes).
Then slides were removed from the stainer, washed in water
with a drop of dishwashing detergent and mounted. These
immunohistochemical stainings detected the presence or
absence of the protein products of the MMR genes MLH1,
PMS2, MSH2 and MSH6. The pattern of their loss provides
information about which gene is not functioning properly. IHC
staining was evaluated under a light microscope as follows:
nuclear expression of all MMR proteins indicates an MMR-
proﬁcient tumor status, loss of nuclear expression of any of the
proteins indicates an MMR-deﬁcient tumor status.
Statistical analysis
The distributions of all continuous data set were analyzed for
normality by the Shapiro-Wilk normality test. Differences
between paired groups of data were analyzed by either paired t
test or Wilcoxon matched pairs test according to their distribu-
tion. Differences between different groups of patients were ana-
lyzed by either unpaired t test or Mann-Whitney test according
to their distributions. Correlation was analyzed by either Pear-
son or Spearman correlation test according to their distribu-
tions. These statistical analyses were performed using
GraphPad Prism 5 (GraphPad Software). Hierarchical cluster-
ing was analyzed by one minus Pearson correlation using
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GENE-E (Broad Institute). Progression-free survival (time to
recurrence) was calculated from the date of LM-CRC surgery
to the date of event (LM-CRC recurrence), or the date of last
follow-up. Patients lost to follow-up were censored as of the
last day of follow-up. Survival curves were estimated by the
Kaplan-Meier mothed. The Breslow test was used to assess dif-
ferences between survival curves of different groups. For multi-
variable analysis, the Cox proportional Hazard regression
analysis was used. These statistical analyses were performed
using SPSS Statistics 21 (IBM). P values less than 0.05 were
considered statistically signiﬁcant (p < 0.05; p < 0.01; p
< 0.001).
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